Bone Marrow TransplantationTransplantation, HomologousGraft vs Host DiseaseBone MarrowBone Marrow CellsWhole-Body IrradiationTransplantation, AutologousLeukemiaAnemia, AplasticTransplantation ConditioningTransplantation ChimeraBusulfanTissue DonorsHematopoietic Stem Cell TransplantationGraft SurvivalLeukemia, Myelogenous, Chronic, BCR-ABL PositiveBone and BonesHistocompatibility TestingHistocompatibilityRecurrenceLeukocyte TransfusionCyclophosphamideRadiation ChimeraLiver TransplantationBone Marrow PurgingGraft vs Tumor EffectLeukemia, Myeloid, AcuteTransplantation, IsogeneicPrecursor Cell Lymphoblastic Leukemia-LymphomaRemission InductionHematologic NeoplasmsGraft vs Host ReactionHematopoietic Stem CellsLymphocyte DepletionAcute DiseaseCombined Modality TherapyHepatic Veno-Occlusive DiseaseImmunosuppressive AgentsMice, Inbred C57BLTreatment OutcomeGraft vs Leukemia EffectLeukemia, MyeloidHematopoiesisTime FactorsLymphocyte TransfusionImmunosuppressionMyelodysplastic SyndromesChimeraGraft RejectionT-LymphocytesTransplantation ImmunologyBone Marrow DiseasesKidney TransplantationRetrospective StudiesNuclear FamilyCyclosporineSyndromeSurvival AnalysisActuarial AnalysisHLA AntigensLymphoma, Non-HodgkinHematologic DiseasesSevere Combined ImmunodeficiencyCytomegalovirus InfectionsBone Marrow ExaminationFatal OutcomeFollow-Up StudiesMice, Inbred BALB CCytarabineSurvival RateStem Cell TransplantationBone RemodelingPostoperative ComplicationsAntineoplastic Combined Chemotherapy ProtocolsBone Marrow NeoplasmsPancytopeniaDisease-Free SurvivalLeukocyte CountHeart TransplantationSpleenGranulocyte Colony-Stimulating FactorColony-Forming Units AssayInfectionEtoposideLymphomaMultiple MyelomaFlow CytometryLung TransplantationPrognosisMethotrexateAnemia, Refractory, with Excess of BlastsLeukemia, Myelomonocytic, AcuteAntilymphocyte SerumCell DifferentiationBone DensityNeoplasm, ResidualImmunophenotypingCyclosporinsImmunocompromised HostProspective Studies